Oslo (Norway), 17 October 2017 – In accordance with the authorisation granted by the Annual General Meeting 29 May 2017, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 90,000 share options to key employees.
The share options are allotted to the newly hired Chief Medical Officer, Hans Olivecrona. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech Holding ASA’s choice), at a strike price of NOK 22.35, equal to the volume weighted average share price (VWAP) for the last 5 days of trade prior to the grant date. The options can be exercised with 1/3 of the options after one year, further 1/3 after two years and the last third after three years. The share options are lapsing in Q3 2022.
After the allocation, Hans Olivecrona holds a total portfolio of 90,000 unexercised share options and 0 shares.
The current authorisation, as of 29 May 2017, allows for allocation of additional 1,040,000 share options to key employees.
For more information, please contact:
Per Walday, CEO, firstname.lastname@example.org, Mobile: +47 917 93 429
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.